Identification of Diagnostic Genes of Aortic Stenosis That Progresses from Aortic Valve Sclerosis
Chenxi Yu,Yifeng Zhang,Hui Chen,Zhongli Chen,Ke Yang
DOI: https://doi.org/10.2147/jir.s453100
IF: 4.5
2024-05-29
Journal of Inflammation Research
Abstract:Chenxi Yu, 1, &ast Yifeng Zhang, 1, &ast Hui Chen, 2, &ast Zhongli Chen, 3 Ke Yang 1 1 Department of Cardiovascular Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, People's Republic of China; 2 Department of Cardiology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200011, People's Republic of China; 3 State Key Laboratory of Cardiovascular Disease, Cardiac Arrhythmia Center, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, People's Republic of China &astThese authors contributed equally to this work Correspondence: Ke Yang, Department of cardiovascular medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 197 Rui Jin Road II, Shanghai, 200025, People's Republic of China, Tel/Fax +86 21 64370045, Email Zhongli Chen, State Key Laboratory of Cardiovascular Disease, Cardiac Arrhythmia Center, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, People's Republic of China, Tel/Fax +861088392295, Email Background: Aortic valve sclerosis (AVS) is a pathological state that can progress to aortic stenosis (AS), which is a high-mortality valvular disease. However, effective medical therapies are not available to prevent this progression. This study aimed to explore potential biomarkers of AVS-AS advancement. Methods: A microarray dataset and an RNA-sequencing dataset were obtained from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) were screened from AS and AVS samples. Functional enrichment analysis, protein–protein interaction (PPI) network construction, and machine learning model construction were conducted to identify diagnostic genes. A receiver operating characteristic (ROC) curve was generated to evaluate diagnostic value. Immune cell infiltration was then used to analyze differences in immune cell proportion between tissues. Finally, immunohistochemistry was applied to further verify protein concentration of diagnostic factors. Results: A total of 330 DEGs were identified, including 92 downregulated and 238 upregulated genes. The top 5% of DEGs (n = 17) were screened following construction of a PPI network. IL-7 and VCAM-1 were identified as the most significant candidate genes via least absolute shrinkage and selection operator (LASSO) regression. The diagnostic value of the model and each gene were above 0.75. Proportion of anti-inflammatory M2 macrophages was lower, but the fraction of pro-inflammatory gamma-delta T cells was elevated in AS samples. Finally, levels of IL-7 and VCAM-1 were validated to be higher in AS tissue than in AVS tissue using immunohistochemistry. Conclusion: IL-7 and VCAM-1 were identified as biomarkers during the disease progression. This is the first study to analyze gene expression differences between AVS and AS and could open novel sights for future studies on alleviating or preventing the disease progression. Keywords: aortic stenosis, aortic valve sclerosis, diagnostic genes, machine learning, immune infiltration, immunohistochemistry According to 2020 American College of Cardiology/American Heart Association guidelines, aortic valve sclerosis (AVS) is defined as aortic valve thickening without flow limitation and with maximum aortic velocity <2 m/s. 1 The prevalence of AVS is 25% to 30% among individuals over 65 years of age. 2 Additionally, one-third of AVS will progress to a certain degree of aortic stenosis (AS) during an average follow-up period of 4 years. 3 AS is defined as aortic valve calcification or fibrosis with a maximum aortic velocity >2 m/s. 1 AS is one of the most prevalent high-mortality valvular diseases, with a 4-year event-free survival rate of only 16%, even in asymptomatic severe AS cases. 4,5 Surgical aortic valve replacement (SAVR) and transcatheter aortic valve implantation (TAVI) can significantly decrease AS mortality. 6,7 However, surgical operations come with risks, such as infections and arrhythmias. 8,9 Unfortunately, effective medical therapies are not available to prevent the progression from AVS to AS. 10,11 Therefore, it is vital to study gene expression differences in AVS and AS and research the role of potential genes to better understand the underlying disease progression mechanism. Previous studies have reported that inflammation contributes to the occurrence of AS and based on the development of -Abstract Truncated-
immunology